Episode
Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2026 American Urological Association Annual Meeting
- Published
- Jun 16, 2026
- Duration seconds
- 7100
- Processing state
not_requested- Canonical source
- https://oncologytoday.captivate.fm/episode/6139-aua2026-prostate
Actions
POST https://stenobird.com/v1/public/podcasts/oncology-today-with-dr-neil-love-1004241/episodes/prostate-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-american-urological-association-annual-meeting/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241/prostate-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-american-urological-association-annual-meeting.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics: Introduction (0:00) Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Shore (2:12) Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak (27:54) Current and Future Role of PARP Inhibitors for Metastatic Prostate Cancer (mPC) — Dr Agarwal (50:49) Emerging Role of AKT Inhibition for Patients with mHSPC — Dr Heath (1:13:12) Current and Future Use of Radiopharmaceuticals for mPC — Dr Saad (1:37:26) CME information and select publications